Luye Pharma Group Ltd (LUP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Luye Pharma Group Ltd (LUP) has a cash flow conversion efficiency ratio of 0.028x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€344.86 Million ≈ $403.18 Million USD) by net assets (€12.19 Billion ≈ $14.26 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LUP equity to assets ratio to measure how much of total assets are equity-financed.
Luye Pharma Group Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Luye Pharma Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Luye Pharma Group Ltd (LUP) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Luye Pharma Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Luye Pharma Group Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Corporación Interamericana de Entretenimiento S.A.B. de C.V
MX:CIEB
|
-0.085x |
|
Prosegur Cash S.A
MC:CASH
|
0.233x |
|
ZEAL Network SE
XETRA:TIMA
|
0.163x |
|
ARIZONA SONORAN COPPER
F:H6F
|
0.013x |
|
Canaccord Genuity Group Inc
TO:CF
|
0.333x |
|
Mivtach Shamir
TA:MISH
|
-0.050x |
|
AMC Entertainment Holdings Inc
NYSE:AMC
|
0.067x |
|
Shenzhen Changhong Tech
SHE:300151
|
0.045x |
Annual Cash Flow Conversion Efficiency for Luye Pharma Group Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Luye Pharma Group Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see LUP company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €18.36 Billion ≈ $21.46 Billion |
€1.78 Billion ≈ $2.08 Billion |
0.097x | +812.06% |
| 2024-12-31 | €15.75 Billion ≈ $18.42 Billion |
€167.76 Million ≈ $196.13 Million |
0.011x | -90.97% |
| 2023-12-31 | €13.53 Billion ≈ $15.82 Billion |
€1.60 Billion ≈ $1.87 Billion |
0.118x | -21.26% |
| 2022-12-31 | €11.04 Billion ≈ $12.91 Billion |
€1.65 Billion ≈ $1.93 Billion |
0.150x | +648.50% |
| 2021-12-31 | €9.11 Billion ≈ $10.66 Billion |
€182.37 Million ≈ $213.21 Million |
0.020x | -84.32% |
| 2020-12-31 | €8.10 Billion ≈ $9.47 Billion |
€1.03 Billion ≈ $1.21 Billion |
0.128x | -15.94% |
| 2019-12-31 | €9.37 Billion ≈ $10.96 Billion |
€1.42 Billion ≈ $1.66 Billion |
0.152x | +15.19% |
| 2018-12-31 | €7.93 Billion ≈ $9.28 Billion |
€1.05 Billion ≈ $1.22 Billion |
0.132x | -5.74% |
| 2017-12-31 | €6.90 Billion ≈ $8.06 Billion |
€964.10 Million ≈ $1.13 Billion |
0.140x | +54.96% |
| 2016-12-31 | €6.56 Billion ≈ $7.67 Billion |
€592.03 Million ≈ $692.14 Million |
0.090x | -- |
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more